AP-HM, Department of Nephrology, Hopital de la Conception, Marseille, France.
Aix-Marseille Univ, C2VN, INSERM 1263, INRA 1260, Campus Timone, Marseille, France.
BMC Nephrol. 2020 Jul 9;21(1):260. doi: 10.1186/s12882-020-01911-9.
The seroprevalence of human Parvovirus B19 (PVB19) is 70-85% in adults worldwide. PVB19 is the etiologic agent of the fifth disease, is a cause of aplastic anemia, and can be associated with kidney injury. We aimed to describe the cases of 4 patients with kidney injury related to PVB19 primary infection, and to evaluate the seroprevalence of PVB19 and the incidence of PVB19 primary infection in patients undergoing a native kidney biopsy.
Cases of PVB19 infection with kidney injury were reviewed from the archives of the department of Nephrology. A systematic screening of anti-PVB19 IgG and IgM antibodies and viral DNA was performed in sera from 100 consecutive patients with a kidney biopsy in 2017-2018.
The 4 patients with PVB19 infection-associated kidney disease displayed: one lupus-like glomerulonephritis (GN) without lupus auto-antibodies, one minimal change disease with tubular necrosis, one secondary hemolytic and uremic syndrome and one membrano-proliferative GN. In the 100 patients biopsied, 67 had elevated anti-PVB19 IgG, among whom 8 had elevated IgM, without circulating viral DNA, without any particular renal pathological pattern. One additional patient showed a seroconversion at the time of kidney biopsy, which revealed a class V lupus nephritis.
PVB19 primary infection can be associated with different kidney diseases. The seroprevalence of PVB19 among patients with a kidney biopsy is similar to the overall population, and primary infection is rarely documented (1%) after systematic screening. Whether PV19 is nephrotoxic, or triggers renal endothelial injury and immune activation, remains to be elucidated.
全球成年人的人细小病毒 B19(PVB19)血清阳性率为 70-85%。PVB19 是第五病的病原体,是再生障碍性贫血的病因,并且可与肾损伤相关。我们旨在描述 4 例与 PVB19 原发性感染相关的肾损伤病例,并评估进行肾活检患者的 PVB19 血清阳性率和 PVB19 原发性感染发生率。
从肾脏病学档案中回顾 PVB19 感染伴肾损伤的病例。对 2017-2018 年期间 100 例肾活检患者的血清进行抗 PVB19 IgG 和 IgM 抗体及病毒 DNA 的系统筛查。
4 例 PVB19 感染相关肾病患者的表现分别为:1 例无狼疮自身抗体的狼疮样肾小球肾炎(GN)、1 例微小病变伴肾小管坏死、1 例继发性溶血尿毒综合征和 1 例膜增生性 GN。在接受活检的 100 例患者中,67 例抗 PVB19 IgG 升高,其中 8 例 IgM 升高,无循环病毒 DNA,无特殊的肾脏病理模式。另外 1 例患者在肾活检时出现血清转换,显示为 5 型狼疮肾炎。
PVB19 原发性感染可与不同的肾脏疾病相关。肾活检患者的 PVB19 血清阳性率与总体人群相似,经系统筛查后很少记录到(1%)原发性感染。PVB19 是否具有肾毒性,或引发肾脏内皮损伤和免疫激活,仍有待阐明。